Company Profile

Cerecor Inc.

2400 Boston Street, Suite 324

Baltimore Maryland 21224 U.S.A.
Phone: 410-522-8707 Fax: n/a

Industry
Biopharmaceutical

Segment
Start Up

Company News

Cerecor Inc. Bolsters Clinical Pipeline With Acquisition Of Phase 2-Ready Kappa Opioid Receptor Antagonist From Eli Lilly (LLY) 2/20/2015 8:55:57 AM

Cerecor Inc. To Present At 16th Annual Biotechnology Industry Organization (BIO) CEO & Investor Conference 2/5/2014 8:05:28 AM

Cerecor Inc. Receives Fast Track Designation For CERC-301 For The Treatment Of Major Depressive Disorder 11/25/2013 12:35:12 PM

Cerecor Inc. Announces Initiation of Phase 2 Study for CERC-301, an Oral Rapid-acting Antidepressant Candidate 11/8/2013 10:00:47 AM

Cerecor Inc. to Present at 12th Annual Biotechnology Industry Organization (BIO) Investor Forum 10/2/2013 7:33:47 AM

Cerecor Inc. Raises $6.8 Million in Series A-1 Financing 9/12/2013 7:46:55 AM

Cerecor Inc. to Present at Stifel Nicolaus Healthcare Conference 9/3/2013 7:18:45 AM

Cerecor Inc. to Present at Wedbush Securities Life Sciences Conference 8/13/2013 6:33:53 AM

Cerecor Inc. Granted U.S. Patent for Antitussive FP01 8/9/2013 9:31:30 AM

Cerecor Inc. Acquires Rights to NR2B Receptor Antagonist From Merck & Co., Inc. (MRK) 4/19/2013 9:03:55 AM

//-->